INVESTOR NEWS

Gentian and research partners with two posters related to the value of calprotectin in management of COVID-19 patients at the AACC

Moss, 14.12.2020

New study results confirm the value of calprotectin in management of COVID-19 patients (2020)

Moss, Norway 20.11.2020 Gentian Diagnostics AS is pleased to announce that the results from a study conducted..

Gentian Diagnostics presents at the Pareto Healthcare conference

Moss 02.09.20

STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH SEVERE COVID-19

Moss, 27.08.20

Gentian awarded up to NOK 8.0 million funding to develop a novel high-throughput COVID-19 antibody test

Moss, 3 July 2020

Release of BÜHLMANN fPELA® turbo

Moss 16.06.2020

Calprotectin, a promising biomarker for prediction of severe events in sepsis

Moss 27.03.2019

Calprotectin indicates inflammatory response earlier than PCT and CRP

Moss 27.03.2019 Gentian Diagnostics AS is pleased to announce that the results from a study conducted in..

Financial calendar 2020

Financial calendar for Gentian Diagnostics AS

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..